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Systematic reviewThe development of a radiation induced second primary cancer (SPC) is one themost serious long termcon-
sequences of successful cancer treatment. This reviewaims to evaluate SPC inprostate cancer (PCa) patients
treated with radiotherapy, and assess whether radiation technique inﬂuences SPC. A systematic review of
the literaturewas performed to identify studies examining SPC in irradiated PCa patients. This identiﬁed 19
registrypublications, 21 institutional series and7other studies. There ismarkedheterogeneity inpublished
studies. An increased risk of radiation-induced SPC has been identiﬁed in several studies, particularly those
with longer durations of follow-up. The risk of radiation-induced SPC appears small, in the range of 1 in 220
to1 in 290 over all durations of follow-up, andmay increase to 1 in 70 for patients followedup formore than
10 years, based on studies which include patients treated with older radiation techniques (i.e. non-
conformal, large ﬁeld). To date there are insufﬁcient clinical data to drawﬁrm conclusions about the impact
of more modern techniques such as IMRT and brachytherapy on SPC risk, although limited evidence is
encouraging. In conclusion, despite heterogeneity between studies, an increased risk of SPC following
radiation for PCahas been identiﬁed in several studies, and this risk appears to increase over time. Thismust
be borne in mind when considering which patients to irradiate and which techniques to employ.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 110 (2014) 213–228
Open access under CC BY-NC-ND license.The development of a radiation induced second primary cancer
(RISPC) is one of the most serious long term consequences of suc-
cessful cancer treatment. Patients diagnosed with early or locally
advanced prostate cancer (PCa) face a variety of treatment options,
several of which involve ionising radiation: external beam radio-
therapy (EBRT), brachytherapy (BT) or combination EBRT and BT
(EBRT–BT) might be employed. Modern radiotherapy techniques
such as IMRT result in changes in dose distribution and scatter
which have resulted in theoretical concerns about an increased risk
of RISPC [1]. Patients are now diagnosed with PCa at an earlier
stage than in the past and so may receive treatment sooner in
the course of the disease. In addition, patients now survive for
longer following their diagnosis. As such the long term conse-
quences of treatment, including the risk of RISPC, become particu-
larly relevant.
Studies of Atomic bomb survivors demonstrated that there is a
latency period of at least ﬁve years before the development of solid
RISPCs [2]. A second primary cancer (SPC) is generally consideredradiation induced if: (i) it is diagnosed after a latency period (usu-
ally considered to be 5 years or more) following irradiation, (ii) it
occurs within the radiation ﬁeld (for prostate radiotherapy, this in-
cludes the rectum, bladder, anus, prostate, soft tissues, bones or
joints of the pelvis and pelvic lymphoma), (iii) it is a different his-
tological type to the original cancer and (iv) the second tumour
was not evident at the time of radiotherapy [3,4]. More commonly,
PCa patients may develop subsequent SPCs which are not radio-
therapy induced, but are the result of genetic and environmental
factors. The distinction between RISPC and SPC can become blurred
as regions beyond the primary radiation ﬁeld are exposed to scat-
tered doses of radiation, and theoretically these may increase the
risk of RISPCs in out-of-ﬁeld regions.
When evaluating SPCs in irradiated PCa patients, registry dat-
abases provide very large numbers of patients for analysis, and
therefore have sufﬁcient power to observe differences between pa-
tient groups. The information within registries, however, is less
complete than that from institutional series. In depth details
regarding treatment are often absent and details of potential con-
founding factors (e.g. smoking status) are often not recorded. Reg-
istries may also suffer from under-reporting of SPCs, particularly in
elderly patients.
214 Second primary cancer after prostate radiotherapyInstitutional data provide more detailed information and so
confounding factors may be easier to identify. Patient numbers,
however, are smaller and therefore power to detect real differences
in SPC incidences is limited. Institutional data do not come with its
own ‘normal population’ for comparison, and so external compar-
ators must be used. Some institutional studies only report crude
rates of SPC, rather than making comparisons with SPC in non-irra-
diated patients or the general population, thus limiting the useful-
ness of these data. Series examining survival following prostate
irradiation may report number of deaths due to SPCs but again, risk
comparisons may not be performed.
This work reviews published registry and institutional data
with particular regard to the impact of treatment technique on
the risk of second cancers.
Objectives
To evaluate SPCs in PCa patients treated with radiotherapy, and
to evaluate whether different radiotherapy techniques result in dif-
ferent risks of SPCs.
Methods
A systematic search of the literature was performed using Med-
line, EMBASE and CENTRAL databases. Search terms were related to
SPC and RISPC, and radiotherapy and PCa. References and ‘‘related
articles’’ of relevant articles were also reviewed. Studies in English
which reported rates of, or mortality from, any SPC, rectal cancer or
bladder cancer following radical irradiation for prostate adenocar-
cinoma were included. Studies published in full text and abstract
form were included. Studies involving radiotherapy for paediatric
and non-adenocarcinoma PCa were excluded. Studies examining
prostate cancers as a whole, without speciﬁcally examining SPC risk
in irradiated PCa patients, were also excluded. Case studies and ser-
ies limited to 10 or fewer patients, and studies examining palliative
radiotherapy alone, were excluded. The last search was performed
on the 10th September 2013. This strategy identiﬁed 651 different
articles. Reasons for exclusion included articles: not dealing with
SPC (n = 241), planning studies (n = 101), primary tumour not spe-
ciﬁcally adenocarcinoma PCa (n = 74), about management of SPC
but not risk (n = 3), review articles (n = 53), case reports (n = 25),
not in English language (n = 24), patients treatedwith non-standard
therapy (e.g. high dose chemotherapy; n = 6), letters/editorials
without new data (n = 19), studies reporting laboratory based work
(n = 6), early versions of later full study (n = 14), patients treated
with palliative therapies alone (n = 20), studies examining risks
related to concomitant imaging (n = 3), studies not examining irra-
diated PCa patients speciﬁcally (n = 2), studies examining speciﬁc
second cancer other than rectal or bladder cancer (n = 3) and stud-
ies that did not speciﬁcally evaluate risks from PCa radiation
(n = 10). In total, 14 SEER, 5 other registries, and 21 institutional
studies were identiﬁed as well one paper reporting the results of
a screening trial that examined second cancers and 6 studies
reporting mortality due to SPC (see Fig. 1).
Results
The majority of evidence addresses SPC and RISPC in patients
treated with primary EBRT (mainly in the form of non-conformal
and 3D-conformal (3D-CRT) techniques) which is discussed ini-
tially, considering risk of SPC overall, then rectal and bladder can-
cer, before evaluating SPCs following other irradiation techniques.
Throughout this review, crude rates are stated as such, and wher-
ever available, adjusted risk ratios and comparisons are presented
in preference to unadjusted ﬁgures.Overall second cancer risk associated with EBRT for prostate cancer
Compared to the general population, all four registry studies did
not ﬁnd irradiated patients to be at any signiﬁcantly increased risk
of SPC, both when considering all durations of follow-up (i.e. be-
yond any exclusion periods) and also when considering follow-
up beyond 5 years [5–7] (Table 1). Although not reaching the
threshold for statistical signiﬁcance, Rapiti et al. did conclude that
compared to the general population, irradiated PCa patients were
at a slightly increased risk beyond 5 years which the group consid-
ered to be of ‘‘borderline signiﬁcance’’ (p = 0.056) [8]. Brenner et al.
found irradiated PCa patients to be at a signiﬁcantly reduced risk of
SPCs (standardised incidence ratio (SIR): 0.89) compared to the
general population, although when patients under the age of 60
were considered alone, this deﬁcit was no longer observed [6].
The low SPC incidence observed amongst irradiated PCa patients
was attributed to the relatively elderly population evaluated. Bag-
shaw et al., a single institution study, also found irradiated patients
not to be at increased risk of SPC compared to the general popula-
tion [9].
Comparing irradiated PCa patients with a non-irradiated PCa
cohort may be considered more representative than comparisons
with the general population, and in this situation different results
are observed to those above (Table 2). All four registry studies
found irradiated patients to be at increased risk of SPC compared
to non-irradiated PCa patients [5,6,10,11]. This increased risk be-
gan after 1 year of follow-up in two of these studies [5,10], and
was observed after 5 years of follow-up in the three studies which
speciﬁcally examined this time period [6,10,11].Risk increased fur-
ther beyond 10 years of follow-up in the one study which exam-
ined this period [6]. Similarly, data from prostate patients treated
within the PLCO (prostate, lung, colorectal and ovarian) screening
trial demonstrated that irradiated PCa patients had a signiﬁcantly
increased risk of any second cancer (incidence: 15.5/1000 per-
son-years in irradiated patients vs. 11.4/1000 person-years in
non-irradiated patients) beyond 30 days and beyond 5 years [12].
In terms of single institution studies, Huang et al. compared SPC
incidence between 2120 irradiated and 2120 surgically treated pa-
tients within a matched-pair analysis [13]. Most irradiated patients
were treated with EBRT alone (as opposed to with EBRT–BT). Over
all durations of follow-up there was no signiﬁcant increased risk of
SPC in irradiated patients, but, in keeping with the registry studies
above, after 5 and 10 years there was a signiﬁcant increase in risk
of SPC in irradiated patients. After 10 years this risk was almost 5
times that of surgical patients [13]. In contrast, Movsas et al., the
smallest study examined here, and the study with the shortest
median follow-up, found irradiated PCa patients to be at no in-
creased risk of SPC over all durations of follow-up, from 5 to
9.9 years, and beyond 10 years, compared to PCa patients from
the SEER database (of whom only 12.5% were irradiated) [14].
Single institution studies reporting crude rates of SPC (Supple-
mentary Material Table 1) include Johnstone et al. who reported
a crude SPC rate of 17.5% beyond one year of PCa diagnosis, in a
series of 154 irradiated patients after a median potential follow-
up of 10.9 years [15]. This was not signiﬁcantly different to the rate
of non-prostate cancers diagnosed prior to PCa diagnosis
(p = 0.288). Gardner et al. and Zilli et al. reported crude rates of
2.6% over all durations of follow-up and 5.4% beyond 6 months of
follow-up respectively [16,17]. Long term trial results reported
by Bolla et al. revealed a crude rate of SPCs in irradiated patients
of 7.7% over all durations of follow-up [18]. Median follow-up is
variable between these studies, and no comparisons with
other population groups are performed, limiting the usefulness
of these ﬁgures.
Studies examining mortality in irradiated PCa patients (Supple-
mentary Material Table 2) reveal that up to to 4.1% of patients
Fig. 1. Schema of article selection process.
Table 1
Studies examining second primary cancers at any site in prostate cancer patients irradiated using external beam radiotherapy compared to general population.
Study Type of
data
Period
examined
No.
patients
Median
follow-up
(years)
Exclusions Time
period(s)
assessed
Risk of second cancer
at any site (based on
p < 0.05 or conﬁdence
interval not including 1.0)
Magnitude of risk
(SIR, 95% conﬁdence
interval or p value in
parentheses if available)
Pawlish (1997) [5] Retrospective,
SEER registry
1973–
1982
2087 6.1 (mean FU
reported)
<1 year FU >1 year FU No difference 1.03 (0.91–1.16)
Brenner (2000) [6] Retrospective,
SEER registry
1973–
1993
51,584 4 (mean FU
reported)
<2 months >2 months Reduced 0.89*
>5 years Reduced 0.92*
>10 years Reduced 0.96*
Pickles (2002) [7] Retrospective, British
Columbia Tumor
Registry
1984–
2000
9890 4.77 <2 months >2 months No difference 1.01 (p = 0.9)
2 months–5
years
No difference 0.96 (NS*)
>5 years No difference 1.08 (NS*)
>10 year No difference 1.12 (NS*)
Rapiti (2008) [8] Retrospective, Geneva
Cancer Registry
1980–
1998
264 7.8 <5 years >5 years No difference** 1.35 (p = 0.056)
5–9 years No difference 1.28 (NS*)
P10 years No difference 1.55 (NS*)
Bagshaw (1988) [9] Retrospective, single
institution
1956–
1985
914 NR None All periods No difference 0.93 (p = 0.48)
SIR: standardised incidence ratio, NR: not reported, NS: not signiﬁcant, FU: follow-up.
* p Value and/or conﬁdence interval not reported.
** The group concluded irradiated patients were at a slightly increased risk which was ‘‘of borderline signiﬁcance’’.
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above, duration of follow-up is different in all studies and so theseﬁgures must be interpreted with caution [14,18,19]. In one study,
10% of all deaths were the result of second malignancies [20].
Table 2
Studies examining second primary cancers at any site in prostate cancer patients irradiated using external beam radiotherapy compared to non-irradiated prostate cancer
patients.
Study Type of data Period
examined
No. patients Median
follow-up
(years)
Exclusions Time
period(s)
assessed
Risk of second cancer at
any site (based on p < 0.05
or conﬁdence interval not
including 1.0)
Magnitude of risk (relative
risk or other where stated
(95% CI or p value if
available))
Pawlish (1997) [5] Retrospective, SEER
registry
1973–
1982
2087 RT 6.1 (mean) <1 year >1 year Increased 1.23 (1.06–1.42)
6390 no RT
Brenner (2000) [6] Retrospective, SEER
registry
1973–
1993
51,584 RT 4 (mean) <2 months Percentage increase in risk:
70,539 no RT >2 months No difference 4 (1 to 9, p = 0.08)
>5 years Increased 11 (3–20, p = 0.007)
>10 years Increased 27 (9–48, p = 0.002)
Abdel-Wahab
(2008) [10]
Retrospective, SEER
registry
1973–
2002
48,400 RT 5.3 RT <1 year >1 year Increased HR: 1.137 (1.087–1.190)
40,733 no RT 4.3 no RT >5 years Increased HR: 1.263 (1.167–1.367)
De Gonzalez
(2011) [11]
Retrospective, SEER
registry
1973–
2002
76,363 RT 9.4 RT
(mean)
<5 years >5 years Increased 1.26 (1.21–1.30)
123,800 no RT 10.1 no RT
(mean)
Movsas (1998)
[14]
Retrospective, Single
Institution
1973–
1993
543 RT 3.9 RT <2 months Crude rates (RT vs. no RT):
18,135 no RT* 3.9 no RT
(mean)
>2 months No difference 5.7% vs. 5.8% (p = 0.99)
>2 months–
9 years
No difference 0.74% vs. 0.9% (p = 0.89)
1–4.9 years No difference 3.8% vs. 3.6% (p = 0.95)
5–9.9 years No difference 4.3% vs. 4.4% (p = 0.89)
>10 years No difference 0% vs. 8.3% (p = 0.56)
Huang (2011) [13] Retrospective, Single
Institution matched-
pair analysis
1984–
2005
2120 RT 7.15 RT None All durations No difference HR: 1.14 (0.94–1.39)
2120 no RT 6.99 no RT >5 years Increased HR: 1.86 (1.36–2.55)
>10 years Increased HR: 4.94 (2.18–11.2)
Black (2013) [12] Prospective, trial data 1993–
2001
3216 RT 6 (mean) >30 days >30 days Increased 1.25 (1.1–1.5)
4263 no RT >5 years Increased 1.6 (1.2–2.1)
RT: external beam radiotherapy, HR: hazard ratio, CI: conﬁdence interval, NR: not reported.
 If follow-up for each treatment group reported separately, then this is presented.
* Non-RT patients from Connecticut Cancer Registry, approximately 12.5% received RT despite being considered as ‘no RT’ group.
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demonstrated in irradiated patients compared to the general pop-
ulation. There is more consistent evidence, however, of an increase
in SPC risk in comparison to non-irradiated PCa patients, particu-
larly with increasing durations of follow-up. This raises the possi-
bility that PCa patients are different to the general population, and
so non-irradiated PCa patients and the general population should
not be considered equivalent.
Patient age has an impact on SPC incidence, as illustrated by
Brenner et al. above [6]. Length of follow-up is also important,
and studies with shorter durations of follow-up may not detect
all SPCs. Brenner et al. and Huang et al. illustrated that the relative
risk of SPC in irradiated patients increased over time compared to
surgically treated patients [6,13]. Brenner et al. demonstrated a 6%
increase in relative risk overall for any second solid cancer, which
increased to 15% and 34% beyond 5 and 10 years respectively. In
absolute terms, the risk of radiation-associated SPC was 1 in 290
over all durations of follow-up, 1 in 125 beyond 5 years and 1 in
70 for those surviving beyond 10 years[6]. Similarly, Pickles et al.
reported a crude risk estimate of 1 in 220 over all durations of fol-
low-up, which is not dissimilar [7].Second rectal cancer risk associated with EBRT for prostate cancer
Amongst the ﬁve SEER registry studies examining rectal cancer
in irradiated PCa patients compared to the general population
(Table 3), three show no increase in rectal cancer risk [5,21,22],
while the remaining two, the only two which examined follow-
up beyond 10 years, found an increased risk in irradiated patients
which only began beyond 10 years [6,23]. Of the three non-SEER
registry studies, one found no increase in risk from irradiation be-
yond 5 years, nor beyond 10 years [8] although the number of irra-
diated PCa patients was relatively small, while anotherdemonstrated increased risk of rectal cancer following irradiation
beyond 6 months and beyond 5 years of follow-up [24], and the
third demonstrated increased risk of colorectal cancer beyond
2 months of follow-up and between 2 months and 5 years of fol-
low-up, but not beyond 5 years or beyond 10 years [7].
Of the two single institution studies examining rectal cancer in
irradiated PCa patients compared to the general population, one
found no difference in the risk of rectal cancer following irradiation
over all durations of follow-up [9], and one found an increased risk
within 1 year of follow-up only [15].
Seven of the ten SEER registry studies comparing second rectal
cancer incidence between irradiated and non-irradiated PCa pa-
tients demonstrated that irradiated patients were at increased risk
(Table 4) [6,10,11,22,23,25,26]. This increased risk has been mainly
observed after longer durations of follow-up (i.e. beyond 5 and
10 years), and appears to increase with increasing durations of fol-
low-up. For example, the hazard ratios reported by Nieder et al., in-
crease from 1.11 when considering follow-up from 6 months to
5 years (non-signiﬁcant) to 1.39 (signiﬁcant) between 5 and
10 years of follow-up to 1.79 (signiﬁcant) from beyond 10 years
[22]. Two of the ten SEER studies report no increase in the risk of
second rectal cancer, one of which examined follow-up beyond
5 years speciﬁcally [5,27]. The one remaining SEER study, by Ken-
dall et al., demonstrated that the speciﬁc comparator group with
which irradiated PCa patients are compared might impact on the
relative risk observed: when irradiated PCa patients were com-
pared to patients treated surgically, there was a signiﬁcantly in-
creased risk of rectal cancer in irradiated patients, while
compared to patients who did not receive RT or surgery, the risk
of rectal cancer was signiﬁcantly less, which the group felt was
unrealistic [28]. Thus risk ratio was inﬂuenced by comparator
group. The group therefore suggested an unidentiﬁed con-
founding factor was inﬂuencing results, and, after further analysis,
Table 3
Studies examining second rectal and second bladder cancers in irradiated prostate cancer patients compared to general population.
Study Type of
data
Period No.
patients
Median
follow-up
(years)
Exclusions Time
period(s)
assessed
Risk of second
rectal cancer
(based on p < 0.05
or conﬁdence
interval not
including 1.0)
Magnitude of
risk of rectal
cancer (SIR
(95% CI or p
value if
available)
Risk of second
bladder cancer
(based on p < 0.05
or conﬁdence
interval not
including 1.0)
Magnitude of
risk of bladder
cancer (SIR
(95% CI or p
value if available)
Neugut (1996) [21] Retrospective,
SEER registry
1973–1990 34,889 NR <6 months >6 months–5 years Reduced 0.7 (0.5–0.9) No difference 1.0 (0.8–1.2)
5–8 years No difference 0.8 (0.5–1.2) No difference 1.3 (1.0–1.7)
>8 years No difference 0.8 (0.4–1.3) Increased 1.5 (1.1–2.0)
Pawlish (1997) [5] Retrospective,
SEER registry
1973–1982 2087 6.1 (mean) <1 year >1 year No difference 0.95 (0.45–1.74) Increased 1.49 (1.07–2.02)
>5 years NR NR Increased 1.60 (1.05–2.35)
Brenner (2000) [6] Retrospective,
SEER registry
1973–1993 51,584 4 (mean) <2 months >2 months Reduced 0.82* Increased 1.10*
>5 years Reduced 0.95* Increased 1.20*
>10 years Increased 1.18* Increased 1.32*
Nieder (2008) [22] Retrospective,
SEER registry
1988–2003 93,059 4.1 6 months >6 months No difference 0.99 (0.90–1.10) Increased 1.42 (1.34–1.50)
Huo (2009) [23] Retrospective,
SEER registry
1973–2005 211,882 NR None All No difference 1.04 (0.97–1.11) NR NR
<6 months No difference 0.99 (0.77–1.27)
6 months–5 years No difference 0.96 (0.88–1.05)
>5–10 years No difference 1.06 (0.93–1.20)
>10 years Increased 1.44 (1.22–1.71)
Pickles (2002) [7] Retrospective, British
Columbia Tumor Registry
1984–2000 9890 4.77 <2 months >2 months Increased 1.21 (p 6 0.01) No difference 1.04 (NS*)
>2 months to 5 years Increased 1.21(p 6 0.05) No difference 0.86 (NS*)
>5 years No difference 1.24 (NS*) No difference 1.30 (NS*)
>10 years No difference 1.01 (NS*) No difference 1.64 (NS*)
Rapiti (2008) [8] Retrospective, Geneva
Cancer Registry
1980–1998 264 7.8 <5 years >5 years No difference 2.0 (0.2–7.2) No difference 1.84 (NS*)
>5–9 years No difference 1.2 (0.04–6.9) No difference 0.80 (NS*)
P10 years No difference 5.3 (0.2–29.3) No difference 5.15 (NS*)
Margel (2011) [24] Retrospective, Israel
Cancer Registry
1982–2005 2163 11.2 <6 months >6 months Increased 1.81 (1.2–2.5) NR NR
>5 years Increased 1.30 (1.05–2.8)
Bagshaw (1988) [9] Retrospective, single
institution
1956–1985 914 NR None All No difference 0.54 (p = 0.21) No difference 1.08 (p = 0.8)
Johnstone (1998) [15] Retrospective, single
institution
1974–1988 154 10.9 (potential
follow-up)
None <1 year Increased p < 0.001** Increased p < 0.001**
1–4 years No difference p = 0.64** No difference p = 0.88**
4–10 years No difference p = 0.80** No difference p = 0.75**
>10 years No difference p = 0.69** No difference p = 0.66**
Chrouser (2005) [31] Retrospective, single
institution
1980–1998 1743 7.1 (mean) <30 days >30 days NR NR No difference 0.798 (0.511–1.187)
>30 days to 1 year No difference 0.292 (0.007–1.619)
1–4 years No difference 0.909 (0.469–1.586)
5–9 years No difference 0.665 (0.267–1.367)
10–19 years No difference 1.37 (0.373–3.507)
Singh (2005) [32] Retrospective,
single institution
1996–2003 210 NR <6 months >6 months NR NR Increased 7.27 (3.132–14.331)
SIR: standardised incidence ratio, CI: conﬁdence interval, NR: not reported, NS: not signiﬁcant.
* No p value or conﬁdence interval provided.
** SIRs and conﬁdence intervals not reported.
 Risk reported is for colorectal cancer.
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218 Second primary cancer after prostate radiotherapyconcluded that there was insufﬁcient evidence to conﬁrm that irra-
diation for prostate cancer induced rectal cancer [28]. Indeed, Ken-
dal et al.’s update from 2007 did not demonstrate any increase in
the risk of second rectal cancer in irradiated patients over all dura-
tions of follow-up or beyond 5 years [27].
Of the three non-SEER registry studies comparing second rectal
cancer risk in irradiated PCa patients and non-irradiated patients,
all of which contain fewer patients than the SEER studies, two
demonstrate an increase in risk in irradiated patients, in one from
2 months onwards, and in the other beyond 5 years [7,29]. The
third non-SEER registry study demonstrated no increase in the risk
of second rectal cancer in those irradiated from 30 days [30].
The one single institution study which compared second rectal
cancer risk between irradiated and non-irradiated patients, did so
in the context of a matched-pair analysis. Patient numbers were
smaller than in the above registry studies. No increase in risk in
irradiated PCa patients was observed, both when considering risk
from early on in the follow-up period, and after longer time periods
[13]. Similarly, results of the PLCO trial found irradiated PCa pa-
tients to be at no increased risk of second colorectal cancers be-
yond 30 days compared to non-irradiated patients [12].
Two studies report crude rates of rectal cancer in irradiated PCa
patients without comparison to other population groups. Crude
rates of 2.6% after a median follow-up of 13.1 years are reported
in one series, and of 1.8% after a median follow-up of 3.5 years in
another [16,17] (Supplementary Material Table 1).
Clearly there are discrepancies between studies. There is a sug-
gestion, however, that where an increased risk of rectal cancer is
observed, this is mainly when follow-up beyond 5 or 10 years is in-
cluded in the evaluated time period. Beyond 5 years, cancers may
be considered radiation induced [6,22–26,28,29]. Trials with short-
er durations of follow-up, or few patients with follow-up beyond 5
or 10 years, therefore may not detect all the second rectal cancers
that develop and therefore underestimate the true rate. Indeed, the
study by Rapiti et al. demonstrated that the median time to colo-
rectal cancer was 8.8 years, while median follow-up was only
7.4 years for all patients, which was therefore insufﬁcient to detect
all second colorectal cancers [8]. One study revealed an increase in
rectal cancer within 1 year of follow-up but not beyond [15]. This
could be attributed to surveillance bias, whereby patients with rec-
tal symptoms following RT are investigated and incidental rectal
cancers are detected [15].
The increased risk of second rectal cancer is more consistently
observed when irradiated PCa patients are compared to non-irradi-
ated patients, as opposed to when irradiated patients are compared
to the general population, again highlighting that there are differ-
ences between comparator groups. Differences in length of follow-
up between treatment groups may contribute to these discrepan-
cies. Since the risk of developing SPC increases with time, failure
to adequately correct for duration of follow-up, may result in inac-
curate conclusions. This particular criticism was levelled at Moon
et al. (who demonstrated an increased risk of second rectal cancer
in irradiated patients compared to non-irradiated PCa patients) by
Kendal et al. (who, after correcting for duration of follow-up, dem-
onstrated no increase in risk in irradiated patients) [26,27]. Subse-
quent studies which have also adjusted for length of follow-up,
however, have demonstrated an increase in rectal cancer risk com-
pared to non-irradiated patients and the general population
[10,11,22,23,29].
Another important factor is selection bias: although detailed
information from registries is generally not available, it is possible
that surgically treated patients as a whole have less co-morbidity
than patients treated with radiotherapy. These patients may also
have fewer risk factors for rectal cancer. Age also impacts on the
risk of rectal SPC [25,28], and the majority of the studies have tried
to adjust for this [5–8,14,21–30]. Indeed, de Gonzalez et al. demon-strated that the risk of developing a second cancer within a region
irradiated to high dose (>5 Gy, includes the rectum and bladder)
lessened with an increasing age at diagnosis of PCa, to become
non-signiﬁcant for patients diagnosed with PCa aged 75 years or
greater [29].
In terms of absolute risks, Baxter et al. reported the risk of sec-
ond rectal cancer over 10 years (from 5 to 15 years) as 5.1 per 1000
for surgically treated patients and 10 per 1000 for patients treated
with radiotherapy [25]. Over a median of 10 years (beginning from
6 months of PCa diagnosis), Margel et al. calculated a similar abso-
lute risk of 13 per 1000 in irradiated patients [24].Second bladder cancer risk associated with EBRT for prostate cancer
All four SEER studies which compared the risk of bladder cancer
in irradiated PCa patients with the general population (Table 3) re-
port increased risk in irradiated patients, albeit over different peri-
ods of follow-up: three report increased risk beginning from early
in the follow-up period and, where examined, persisting beyond 5
and 10 years [5,6,22], while one study reports increased risk begin-
ning after 8 years, and not before[21]. The two non-SEER registries
comparing risk of second bladder cancer in irradiated patients
compared to the general population report no difference in risk
within 5 years, beyond 5 years and beyond 10 years of follow-up,
although the study by Rapiti is relatively small [7,8]. Amongst
the four single institution studies comparing risk in irradiated pa-
tients with the general population, two show no increase in the
risk of bladder cancer in irradiated patients over all the follow-
up periods examined (including 10–19 years in one study) [9,31].
Of the other two institutional studies, one demonstrated increased
risk within 1 year of follow-up, but no increase in risk beyond this
period [15], and the other showed increased risk beyond 6 months
[32].
All but one of the 11 registry studies which compare the risk of
second bladder cancer with non-irradiated PCa patients, show a
consistently increased risk of second bladder cancer
[5,6,10,11,22,26,27,29,30,33] (Table 4). The increased risk is often
seen from early on in the follow-up period and frequently persists
beyond 5 and, if assessed, beyond 10 years. The one study which
demonstrates no increased risk is that by Pickles et al. who exam-
ined risk from 2 months and did not speciﬁcally examine longer
time periods [7].
Of the three single institution studies comparing the risk of sec-
ond bladder cancer in irradiated PCa patients compared to non-
irradiated PCa patients, two show no difference in risk from early
in the follow-up period [14,32], while the remaining study shows
increased risk in irradiated patients over all durations of follow-
up and beyond 5 and beyond 10 years [13] (Table 4). Results for
irradiated PCa patients from the PLCO trial suggest no difference
in the risk of second bladder cancer beyond 30 days in irradiated
and non-irradiated patients [12].
In terms of single institution studies reporting crude rates of
second bladder cancers (Supplementary Material Table 1), Zilli
et al. reported a crude rate of 1.1% in a series of 276 patients with
median follow-up of 42.3 months, and Gardner et al. reported no
cases of bladder cancer in a series of 39 patients followed up for
a median of 13.1 years [16,17]. In both studies, risk comparisons
were not performed.
Overall therefore, there does appear to be an increase in the risk
of second bladder cancer in irradiated PCa patients, particularly
when compared to non-irradiated PCa patients. As was observed
when considering second rectal cancer, the increased risk of sec-
ond bladder cancer from irradiation is less consistently observed
when comparisons are made with the general population. In the
case of institutional data, small patient numbers may be the
reason for this. Amongst registry data, there may be fundamental
Table 4
Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using EBRT compared to non-irradiated prostate cancer patients.
Study Type of
data
Period No.
patients
Median
follow-up
(years)W
Exclusions Time
period(s)
assessed
Risk of second
rectal cancer
(based on
p < 0.05
or conﬁdence
interval not
including 1.0)
Magnitude of risk of
second rectal
cancer
(relative risk or
other
where stated (95%
CI
or p value if
available))
Risk of second
bladder
cancer (based
on
p < 0.05
or conﬁdence
interval
not including
1.0)
Magnitude of risk of
second
bladder cancer
(relative
risk
or other where stated
(95% CI or p value if
available))
Pawlish 1997 [5] Retrospective,
SEER registry
1973–1982 2087 RT
6390 no RT
6.1 (mean) <1 year >1 year No difference NR Increased OR: 1.63 (p < 0.05)§
Brenner (2000) [6] Retrospective,
SEER registry
1973–1993 51,584 RT
70,539 no RT
4 (mean) <2 months Percentage increase in
risk:
Percentage increase in
risk:
>2 months No difference 2 (18 to 18,
p = 0.87)
Increased 15 (2–31, p = 0.02)
>5 years No difference 35 (1 to 86, p = 0.06) Increased 55 (24–92, p < 0.01)
>10 years Increased 105 (9–292, p = 0.03) Increased 77 (14–163, p = 0.01)
Baxter (2005) [25] Retrospective,
SEER registry
1973–1994 30,552 RT
55,263 no RT
7.9 RT
8.3 no RT
<5 years >5 years Increased HR: 1.7 (1.4–2.2) NR NR
Kendal (2006) [28] Retrospective,
SEER registry
1973–2001 33,831 RT
167,607 no RT (surgical
patients)
5.1 RT
5.1 no RT
None All Increased 2.38 (2.21–2.55)* NR NR
0–10 years Increased 2.16 (2.00–2.33)
>10 years Increased 15.62 (12.01–19.83)
Kendal (2006) [28] Retrospective,
SEER registry
1973–2001 33,831 RT
36,335 no RT (non-
surgical and no RT
patients)
5.1 RT
3.3 no RT
None All Reduced 0.69 (0.64–0.75)– NR NR
0–10 years Reduced 0.66 (0.61–0.71)
>10 years No difference 0.93 (0.64–1.46)
Moon (2006) [26] Retrospective,
SEER registry
1973–1999 39,805 EBRT 10 <5 years >5 years Increased OR: 1.60 (1.29–1.99) Increased OR: 1.63 (1.44–1.84)
Kendal (2007) [27] Retrospective,
SEER registry
Not stated 520,780 (RT and no RT) NR None All No difference NR No difference NR
>5 years No difference HR: 1.13 (0.98–1.31) Increased HR: 1.23 (1.15–1.32)
Nieder (2008) [22] Retrospective,
SEER registry
1988–2003 93,059 RT
109,178 no RT
4.1 6 months >6 months Increased HR: 1.26 (1.08–1.47) Increased HR: 1.88 (1.70–2.08)
6 months–
5 years
No difference HR: 1.11 (0.90–1.37) Increased HR: 1.69 (1.47–1.94)
5–10 years Increased HR: 1.39 (1.09–1.79) Increased HR: 2.26 (1.89–2.69)
>10 years Increased HR: 1.79 (1.05–3.07) Increased HR: 1.83 (1.31–2.55)
Abdel-Wahab (2008)
[10]
Retrospective, SEER registry 1973–2002 48,400 RT
40,733 no RT
5.3 RT
4.3 noRT
<1 year Percentage increase in
risk:
Percentage increase in
risk:
1–5 years Increased 0.07%, p < 0.001 Increased 0.07% p < 0.001
>5 years Increased 0.16%, p = 0.023 Increased 0.16% p = 0.023
Huo (2009) [23] Retrospective, SEER registry 1973–2005 211,882 RT
424,028 no RT
NR None All Increased 1.91 (1.52–1.89) NR NR
Singh (2010) [33] Retrospective, SEER registry 1973–2005 124,141 RT
163,111 no RT
5.3 RT
4.0 No RT
None All NR NR Increased HR: 1.19 (1.11–1.28)
>6 months Increased HR: 1.33 (1.23–1.44)
>5 years Increased HR: 1.58 (1.38–1.81)
>10 years Increased HR: 1.91 (1.40–2.62)
De Gonzalez (2011)
[11]
Retrospective, SEER registry 1973–2002 76,363 RT
123,800 no RT
9.4 RT (mean)
10.1 no RT
(mean)
<5 years 5–9 years Increased 1.39 (1.29–1.50) Increased 1.39 (1.29–1.50)
10–14 years Increased 1.59 (1.41–1.80) Increased 1.59 (1.41–1.80)
>15 years Increased 1.91 (1.53–2.38) Increased 1.91 (1.53–2.38)
(continued on next page)
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Table 4 (continued)
Study Type of
data
Period No.
patients
Median
follow-up
(years)W
Exclusions Time
period(s)
assessed
Risk of second
rectal cancer
(based on
p < 0.05
or conﬁdence
interval not
including 1.0)
Magnitude of risk of
second rectal
cancer
(relative risk or
other
where stated (95%
CI
or p value if
available))
Risk of second
bladder
cancer (based
on
p < 0.05
or conﬁdence
interval
not including
1.0)
Magnitude of risk of
second
bladder cancer
(relative
risk
or other where stated
(95% CI or p value if
available))
Pickles (2002) [7] Retrospective, British
Columbia Tumor Registry
1984–2000 9890 RT
29,371 no RT
4.77 RT
1.7 no RT
<2 months >2 months Increased
(colorectal)
1.21 (p = 0.03) No difference NR (NS)
Boorjian (2007) [30] Retrospective,
CaPSURE Disease Registry
1989–2003 2471 RT
4608 no RT
3.3 <30 days >30 days No difference NR (p = 0.14) Increased HR: 1.96 (1.12–3.45)
Bhojani (2010) [29] Retrospective, Quebec
Health Plan database
1983–2003 9390 RT
8455 no RT
NR <5 years >5 years Increased HR: 1.9 (p = 0.01) Increased HR: 1.5 (p = 0.01)
>10 years No difference HR: 1.6 (p = 0.5) Increased HR: 2.0 (p = 0.1)
Movsas (1998) [14] Retrospective, Single
Institution
1973–1993 543 RT
18,135 ‘no RT’**
3.9 RT <2 months >2 months NR NR No difference NR
3.9 no RT
(mean)
Singh (2005) [32] Retrospective, single
institution
1996–2003 210 RT
416 no RT
NR <6 months >6 months NR NR No difference NR (No difference
based on
overlapping
conﬁdence
intervals
for SIRs for RT vs.
general
population and no RT
vs.
general population
Huang (2011) [13] Retrospective, Single
Institution matched-pair
analysis
1984–2005 2120 RT
2120 no RT
6.99 RT
7.15 no RT
None All No difference HR: 0.91 (0.39–2.14) Increased HR: 2.02 (1.2–3.41)
>5 years No difference HR: 1.98 (0.36–10.83) Increased HR: 4.49 (1.70–11.85)
>10 years No difference p = 0.31¥ Increased HR: 9.70 (1.23–76.57)
Black (2013) [12] Prospective, trial data 1993–2001 3216 RT
4263 no RT
6 (mean) >30 days >30 days No difference
(colorectal)
1.5 (0.9–2.4) No difference 1.6 (0.9–2.8)
HR: hazard ratio, OR: odds ratio, NR: not reported, NS: not signiﬁcant, CI: conﬁdence interval.
* HR for all time periods also available: 2.42 (95%CI: 2.08–2.81).
** Non-RT patients from Connecticut Cancer Registry, approximately 12.5% received RT despite being considered as ‘no RT’ group.
 Ratio reported for any ‘primary pelvic’ second cancer, considered as rectum, bladder, anus, anal canal, anorectum, prostate and other cancer from the bones, joints and lymphomas based on comparisons of age-adjusted estimates
and not on multivariate Cox regression, as was used for data in other tables.
 Ratio reported for organs considered to be in ‘high dose’ (>5 Gy) sites, includes rectum and bladder.
¥ Hazard ratio not calculated as too few events.
§ Relative risk also reported: 1.59 (95%CI: 1.09–232).
W If follow-up for each treatment group reported separately, then this is presented.
– HR for all time periods also available: 0.69 (95%CI: 0.58–0.82).
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how adequately differences in follow-up are corrected. Under-
reporting may also be a problem in registry data. Selection bias be-
tween surgical and irradiated patients may also have an impact. Of
great importance when considering bladder cancer, is smoking his-
tory and the potential confounding impact this may have. If more
smokers are refused surgery due to co-morbidities, then there will
be excess smokers in irradiated patient cohorts. Registry data fre-
quently do not contain information regarding smoking status. By
comparing the proportion of smokers amongst PCa patients treated
with surgery and RT in an earlier case-control trial, Brenner et al.
suggested that it was unlikely there were excess smokers in the
irradiated patient cohort examined, and therefore concluded that
smoking was unlikely to be a confounding factor [6]. The CAPSURE
disease registry, however, contains data about smoking, and Bho-
jani et al. used this to demonstrate that both smoking and irradia-
tion were independent risk factors for second bladder cancer and
that patients treated with RT who were also smokers were more
than three and a half times more likely to develop bladder cancer
than non-smoking patients who did not receive RT (hazard ratio
(HR): 3.65; 95% conﬁdence interval (CI): 1.45–9.16; [29]).
The increased risk of bladder cancer frequently appears to begin
within 5 years of follow-up in the above studies and so radiation is
not the likely cause of these early bladder tumours. Surveillance
bias, as a result of regular oncological or urological follow-up
may play a part in this, while the impact of smoking may also be
involved in early (i.e. less than 5 years from RT) and late (i.e. be-
yond 5 years of RT) bladder cancer development. Beyond 5 years
the risk of bladder cancer appears to increase further, and radiation
may be attributed to this although the factors mentioned above
should also be considered.Impact of treatment technique: older treatments
The studies discussed above have evaluated SPC incidences in
cohorts where all patients, or the vast majority of patients, re-
ceived EBRT. Many of the SEER analyses have included patients
treated in the 1970s and early 1980s when large pelvic ﬁelds and
cobalt machines were often employed [5,6,10,11,21,23,25,26,28].
SPC risks from these treatments may therefore be different to those
observed with more contemporary techniques. Some studies have
adjusted for the year or era of diagnosis to try to take different
treatment techniques into consideration although date of treat-
ment did not appear to impact SPC risk [22,23,25].Impact of treatment technique: 3D-conformal radiotherapy and IMRT
It is not possible to separate the impact of more conformal EBRT
techniques and older large ﬁeld treatments from most studies. Ini-
tial indications of potential reductions in SPC risk with more con-
temporary treatment techniques were demonstrated by Rapiti
et al., who found a reduction in colorectal cancer incidence in pa-
tients irradiated to higher doses (68–80 Gy) compared to those
treated to less than 67 Gy (RR: 0.2; 95% CI: 0.04–0.91 [8]). This
reduction in risk was attributed to the introduction of smaller vol-
ume conformal radiotherapy techniques which accompanied dose
escalation. Signiﬁcance was lost, however, after adjustment for so-
cio-economic status [8]. In addition, the study by Pickles et al.,
which excluded patients treated with cobalt and included fewer
patients treated with large pelvic ﬁelds, found no increase in the
incidence of SPC overall in irradiated patients compared to the gen-
eral population [7]. The group suggested that it was the increased
use of smaller ﬁelds that resulted in no difference in bladder SPC or
SPC overall, although a signiﬁcant increase in colorectal tumours
was observed over all durations of follow-up (though not beyond
5 and beyond 10 years speciﬁcally) [7]. Two other studies also eval-uated SPC in more contemporary irradiated populations, however,
and these have demonstrated increased bladder SPC risk compared
to the general population and compared to non-irradiated patients
[22,30]. One of these studies also revealed an increase in rectal can-
cer beyond 5 years in irradiated patients compared to non-irradi-
ated patients [22].
Huang et al. was the ﬁrst institutional study to speciﬁcally eval-
uate differences in EBRT treatment technique [13] (Supplementary
Material Table 3). Using a matched-pair analysis comparing irradi-
ated and surgically treated patients in an effort to minimise con-
founding factors, they demonstrated that patients treated with
2D conventional RT were at increased risk of any SPC (HR: 1.76;
95% CI: 1.32–2.35) and bladder cancers (HR: 2.97; 95% CI: 1.50–
5.89). There were no differences in the risk of rectal cancer. In con-
trast, patients treated with 3D-CRT or intensity-modulated radio-
therapy (IMRT), had no increase in the incidence of SPCs overall,
nor in rectal or bladder cancer. The group acknowledged that the
numbers of patients in each RT subset was relatively small (769
in the 2D conventional RT subset and 616 in 3D-CRT/IMRT) and
that the median follow-up in the 3D-CRT/IMRT group was rela-
tively short (4.96 years) in comparison to the 2D conventional RT
group (9.26 years) [13]. Unfortunately numbers were too small to
analyse SPC in patients treated with 3D-CRT and IMRT separately.
Some radiotherapy planning studies, however, have raised theoret-
ical concerns that increased low dose irradiation and leakage (be-
cause of increased monitor unit requirements) with IMRT might
increase SPC incidence [1,34–39].
Zelefsky reported outcomes for a series of 897 patients treated
predominantly with IMRT [40]. After median follow-up of 7 years,
compared to the general population (and excluding non-melanoma
skin cancers), there was no signiﬁcant increase in the development
of any second malignancy beyond 1 and 5 years [40] (Supplemen-
tary Material Table 3). Similarly, compared with the general popu-
lation (again excluding non-melanoma skin cancers), there was no
signiﬁcant increase in risk of second in-ﬁeld and out-of-ﬁeld malig-
nancies beyond 1 and 5 years. Within the analysis the group also
compared the risk of any second malignancy between patients
receiving IMRT (the majority) and 3D-CRT (number of patients
not reported), and no signiﬁcant difference was found (p = 0.59)
[40].
In a second publication, including the same irradiated patient
population with slightly longer follow-up (7.5 years) Zelefsky
et al. compared SPC risks with 1348 patients treated with radical
prostatectomy (median FU 9.4 years) and 413 patients treated with
BT (median follow-up 7.7 years) [41]. There was no signiﬁcant dif-
ference in the rates of second rectal or bladder cancer with treat-
ment type (10 year actuarial likelihood of pelvic second
malignancy: 3%, 4% and 2% for patients treated with surgery, EBRT
and BT, p = 0.29). Multivariate Cox regression revealed that only
age and smoking history were signiﬁcant predictors of SPC, while
treatment type (i.e. surgery, BT or EBRT) was not [41]. Survival fol-
lowing the diagnosis of a second malignancy was no different be-
tween irradiated and surgically treated patients [41].Impact of treatment technique: Brachytherapy
Since the introduction of prostate BT, studies examining the im-
pact of BT on SPC have been published. Four studies have com-
pared SPC incidence after BT with the general population
[22,40,42,43] (Table 5). Two of these studies have examined the
risk of any SPC compared to the general population, and neither
have shown any increase in risk in patients treated with BT, includ-
ing when follow-up beyond 5 years is examined speciﬁcally
[40,42]. The risk of rectal cancer has also been shown to be no
greater than that in the general population over various time
points, including beyond 5 years [22,42]. In terms of bladder
Table 5
Studies examining second primary cancers at any site, second rectal cancers and second bladder cancers in prostate cancer patients irradiated using brachytherapy compared to general population.
Study Type of
data
Period No.
patients
Median
follow-up
(years)
Exclusions Time
period(s)
assessed
Risk of second cancer
at any site based on
p < 0.05 or conﬁdence
interval not including
1.0 (SIR and (95%
conﬁdence interval)
Risk of second rectal
cancer based on
p < 0.05
or conﬁdence interval
not including 1.0 (SIR
and (95% conﬁdence
interval))
Risk of second bladder
cancer based on p < 0.05
or conﬁdence interval
not including 1.0 (SIR
and (95% conﬁdence
interval))
Nieder (2008) [22] Retrospective,
SEER registry
1988–2003 22,889
BT
4.1 <6 months >6 months NR Reduced (0.68
(0.49–0.93))
No difference
(1.10 (0.92–1.31))
Nieder (2008) [22] Retrospective,
SEER registry
1988–2003 17,956 EBRT–BT 4.1 <6 months >6 months NR No difference
(0.86 (0.65–1.14))
Increased
(1.39 (1.19–1.64))
Liauw (2006) [43] Retrospective,
single centre
1987–1994 348 (125 BT, 223
EBRT–BT)
11.4 BT
10.2 EBRT–BT
None All durations NR NR Increased (2.34 (1.26–3.42))
0–1 years No difference (0)
1.1–5 years No difference
(2.80 (0.73–4.87))
5.1–10 years No difference
(2.33 (0.60–4.06))
10.1–20 years No difference
(2.35 (0.05–4.66))
>5 years No difference
(2.34 (0.95–3.72))
Hinnen (2011) [42] Retrospective,
single
institution
1989–2005 1187 7.1 None All durations No difference (0.94 (0.78–1.12)) No difference
(0.90 (0.41–1.72))
No difference
(1.69 (0.98–2.70))
1–4 years No difference (1.03 (0.80–1.30)) No difference
(0.41 (0.05–1.48))
Increased (2.14 (1.03–3.94))
5–15 years No difference (0.78 (0.56–1.04)) No difference
(1.78 (0.71–3.67))
No difference
(0.92 (0.25–2.35))
Zelefsky (2012) [40] Retrospective,
single
institution
1998–2001 413 (322 BT, 91
EBRT (IMRT)–BT)
7.5 <1 year >1 year No difference (0.821 (0.565–1.124)) No difference
(0.753 (0.276–1.465))*
No difference
(0.753 (0.276–1.465))*
>5 years No difference (0.635 (0.304–1.085)) No difference
(0.944 (0.195–2.274))*
No difference
(0.944 (0.195–2.274))*
NR: not reported, BT: brachytherapy, EBRT-RT: combination external beam radiotherapy and brachytherapy, IMRT: intensity-modulated radiotherapy.
 If follow-up for each treatment group reported separately, then this is presented.
* SIR quoted is for any in-ﬁeld cancer, which includes rectal and bladder cancers.
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Table 6
Studies examining second primary cancers at any site in prostate cancer patients irradiated using brachytherapy compared to non-irradiated prostate cancer patients.
Study Type of data Period No. patients Median follow-up
(years)
Exclusions Time period(s)
assessed
Risk of second cancer at any site (based
on
p < 0.05 or conﬁdence interval not
including 1.0)
Magnitude of risk (HR or
other where
stated (95% conﬁdence
interval))
Abdel-Wahab (2008)
[10]
Retrospective, SEER
database
1973–
2002
10,223 BT
40,733 no RT
3.3 BT
4.3 no RT
<1 year >1 year No difference 0.958 (0.869–1.057)
5 years No difference 0.721 (0.435–1.197)
7 years No difference 0.930 (0.575–1.504)
9 years No difference 1.200 (0.736–1.956)
Abdel-Wahab (2008)
[10]
Retrospective, SEER
database
1973–
2002
9096 EBRT–BT
40,733 no RT
3.8 EBRT–BT
4.3 no RT
<1 year >1 year No difference 1.012 (0.920–1.112)
5 years No difference 0.920 (0.699–1.211)
7 years No difference 1.101 (0.910–1.331)
9 years Increased 1.317 (1.053–1.647)
Hinnen (2011) [42] Retrospective, single
institution
1989–
2005
1187 BT
701 no RT
7.1 BT
8.7 no RT
None All durations of FU No difference 0.87 (0.64–1.18)
Huang (2011) [13] Retrospective, single
institution matched-
pair analysis
1984–
2005
333 BT
333 no RT
6.67 BT
6.62 no RT
None All durations of FU No difference 0.53 (0.28–1.01)
Huang (2011) [13] Retrospective, single
institution matched-
pair analysis
1984–
2005
402 EBRT + BT boost
402 no RT
8.81 EBRT–BT
8.87 no RT
None All durations of FU No difference 0.83 (0.50–1.38)
Zelefsky (2012) [41] Retrospective, single
institution
1998–
2001
413 BT
(322 BT, 91 EBRT
(IMRT)–BT)
1348 no RT
7.7 BT
9.4 no RT
None 0–10 years No difference 10 year second cancer
actuarial likelihood BT vs.
surgery: 13% vs. 11%
(p = 0.37)
HR non-signiﬁcant on
multivariate analysis
HR: hazard ratio, BT: brachytherapy, EBRT–BT: combination external beam radiotherapy and brachytherapy, IMRT: intensity-modulated radiotherapy, NS: not signiﬁcant, NR: not reported.
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Table 7
Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using brachytherapy compared to non-irradiated prostate cancer patients.
Study Type of data Period No.
patients
Median
follow-
up¥
(years)
Exclusions Time
period(s)
assessed
Risk of second rectal cancer
(based on p < 0.05 or
conﬁdence interval not
including 1.0)
Magnitude of risk of second
rectal cancer (RR or other
where stated, 95% CI or p
value if available)
Risk of second bladder
cancer (based on p < 0.05 or
conﬁdence interval not
including 1.0)
Magnitude of risk of second
bladder cancer (RR or other
where stated, 95% CI or p
value if available)
Moon
(2006)
[26]
Retrospective, SEER
database
1973–
1999
1285 BT
94,541 no
RT
10 <5 years >5 years No difference OR: 0.3 (NS*) No difference OR: 1.4 (NS*)
Moon
(2006)
[26]
Retrospective, SEER
database
1973–
1999
2219
EBRT–BT
94,541 no
RT
10 <5 years >5 years No difference OR: 1.59 (NS*) No difference OR: 1.08 (NS*)
Abdel-
Wahab
(2008)
[10]
Retrospective, SEER
database
1973–
2002
10,223 BT
40,733 no
RT
3.3 RT
4.3 no RT
<1 year 1–
4.9 years
No difference** 0.01% difference in risk
(NS)**
No difference** 0.01% difference in risk
(NS)**
P5 years No difference** 0.17% difference in risk
(NS)**
No difference** 0.17% difference in risk
(NS)**
Abdel-
Wahab
(2008)
[10]
Retrospective, SEER
database
1973–
2002
9096 EBRT–
BT
40,733 no
RT
3.8 RT
4.3 no RT
<1 year 1–
4.9 years
No difference** 0.09% difference in risk
(NS)**
No difference** 0.09% difference in risk
(NS)**
P5 years No difference** 0.05% difference in risk
(NS)**
No difference** 0.05% difference in risk
(NS)**
Nieder
(2008)
[22]
Retrospective, SEER
registry
1988–
2003
22,889 BT
109,178 no
RT
4.1 6 months >6 months No difference HR: 1.08 (0.77–1.54) Increased HR: 1.52 (1.24–1.87)
6 months–
5 years
No difference HR: 0.96 (0.63–1.44) Increased HR: 1.48 (1.17–1.86)
5–
10 years
No difference HR: 1.49 (0.75–2.94) Increased HR: 1.64 (1.03–2.62)
>10 years No difference HR: 1.13 (0.15–8.42) No difference HR: 0.47 (0.06–3.38)
Nieder
(2008)
[22]
Retrospective, SEER
registry
1988–
2003
17,956
EBRT–BT
109,178 no
RT
4.1 6 months >6 months No difference HR: 1.21 (0.89–1.65) Increased HR: 1.85 (1.54–2.22)
6 months–
5 years
No difference HR: 1.05 (0.71–1.55) Increased HR: 1.81 (1.46–2.25)
5–
10 years
No difference HR: 1.26 (0.69–2.29) Increased HR: 1.80 (1.22–2.67)
>10 years Increased HR: 3.25 (1.25–8.44) No difference HR: 1.64 (0.75–3.59)
Hinnen
(2011)
[42]
Retrospective, single
institution
1989–
2005
1187 BT
701 no RT
7.1 BT
8.7 no RT
None All
durations
of FU
No difference HR: 0.96(p = 0.92) No difference§ HR: 1.13 (p = 0.75)§
Huang
(2011)
[13]
Retrospective, single
institution matched-
pair analysis
1984–
2005
333 BT
333 no RT
6.67 BT
6.62 no RT
None All
durations
of FU
No difference HR: NR (too few events to
analyse), p = 0.32
No difference HR: 0.66 (0.11–3.95)
Huang
(2011)
[13]
Retrospective, single
institution matched-
pair analysis
1984–
2005
402
EBRT + BT
boost
402 no RT
8.81
EBRT–BT
8.87 no RT
None All
durations
of FU
No difference HR: 1.00 (0.14–7.06) No difference HR: 2.98 (0.31–28.7)
Zelefsky
(2012)
[41]
Retrospective, single
institution
1998–
2001
413 BT
(322 BT, 91
EBRT
(IMRT)–BT)
1348 no RT
7.7 BT
9.4 no RT
None 0–
10 years
No difference 10 year actuarial risk BT vs.
surgery: 2% vs. 3% (NS)
No difference 10 year actuarial risk BT vs.
surgery: 2% vs. 3% (NS)
OR: odds ratio, NS: not signiﬁcant, NR: Not reported, HR: hazard ratio, RR: relative risk, CI: conﬁdence interval, BT: brachytherapy, EBRT–BT: combination external beam radiotherapy and brachytherapy, IMRT: intensity-modulated
radiotherapy.
* No p value or conﬁdence interval reported.
** Difference in any ‘primary’ pelvic second primary cancer (includes rectum and bladder) based on comparisons of age-adjusted estimates and not on multivariate Cox regression, as was used for data in previous tables.
 Risk of second cancer in any location in digestive tract.
 Risk of any second pelvic tumour reported.
¥ If follow-up for each treatment group reported separately, then this is presented.
§ Risk of second cancer in urinary tract.
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bladder cancer in patients treated with BT or EBRT–BT over all
durations of follow-up compared to the general population. The
risk was maintained over longer periods of follow-up (and was
equivalent to an absolute excess risk of 35 per 10,000), but did
not reach statistical signiﬁcance [43]. Similarly, Nieder et al. found
patients treated with EBRT–BT to be at increased risk of second
bladder cancer beyond 6 months, while patients treated with BT
monotherapy were not at any increased risk [22]. Hinnen et al.
found an increased risk of second bladder cancer in years 1–4 of
follow-up but not when considering all durations of follow-up,
nor between 5 and 15 years. An increase risk in BT patients aged
less than 60 was also observed (SIR: 5.84; 95% CI: 2.14–12.71)
[42]. In addition, Zelefsky et al. found no difference in the risk of
any in-ﬁeld cancer, which includes rectal and bladder cancers, be-
yond 1 and beyond 5 years of follow-up [40].
Four studies, one registry and three single institution, have
compared the incidence of any SPC in patients irradiated with BT
or EBRT–BT with non-irradiated PCa patients (Table 6)
[10,13,41,42]. Three of the four suggested no increased risk of
any SPC following BT or EBRT–BT [13,41,42]. The fourth study,
importantly, is the largest to examine SPC in patients managed
with BT and speciﬁcally examines longer periods of follow-up
[10]. On multivariate analysis there was no difference in risk for
SPC beyond 1 year for patients treated with BT or EBRT–BT com-
pared to non-irradiated patients (Table 6)[10]. The hazard ratios
for ‘late’ SPCs (i.e. SPC developing beyond 5 years) in patients trea-
ted with BT alone, however, increased over time (0.721 at 5 years,
0.930 at 7 years and 1.2 at 9 years) but did not reach signiﬁcance.
Similarly, the hazard ratios for patients treated with EBRT–BT in-
creased over time and only became signiﬁcant at 9 years (HR of
1.317; 95% CI: 1.053–1.647). Amongst patients treated with BT,
however, the median time to develop ‘late’ SPC was 6.9 years while
the median follow-up amongst BT patients without SPC was only
6.3 years, thus the duration of follow-up was insufﬁcient [10].
With regard to RISPC speciﬁcally (deﬁned as those developing after
5 years in any primary pelvic site, including rectal and bladder tu-
mours), no signiﬁcant difference in risk was observed amongst pa-
tients treated with BT or EBRT–BT compared to patients receiving
neither surgery nor RT [10] (Table 7).
All studies,with one exception,which compare the risk of second
rectal or second bladder cancer (Table 7) in patients managed with
BT or EBRT-RTwith non-irradiated PCa patients do not demonstrate
an increased risk in patients managed with BT or EBRT–BT
[10,13,26,41,42]. The time periods examined are variable, but fol-
low-up beyond 5 years is examined in two of these studies
[10,26]. The one exception is the study by Nieder et al., the largest
study and the only one to speciﬁcally examine risk beyond 10 years.
Patients treated with EBRT–BT were found to be at increased risk of
second rectal cancer beyond 10 years (patients treated with BT
monotherapy were at no increased risk). In addition, patients trea-
ted with BT or EBRT–BT were at increased risk of second bladder
cancer from 6 months, between 6 months and 5 years and between
5 and 10 years [22]. Signiﬁcance was lost beyond 10 years although
fewer patients were followed up for this length of time.
Three studies have compared patients treated with BT with pa-
tients treated with EBRT (Supplementary Material Table 4)
[10,41,44]. None of these have shown PCa patients irradiated with
BTorEBRT–BTtobeat increasedriskof anySPC,norwasany increase
in the risk of pelvic/primary pelvic SPCs observed (in the two studies
which assessed this). While these results are encouraging overall, it
should be remembered that the patient numbers are often lower
than in similar studies which have examined risks in EBRT patients,
and the duration of follow-up may not always be sufﬁcient.
Gutman et al. examined the frequency of colorectal cancers be-
fore and after BT or EBRT–BT [45] (Supplementary Material Ta-ble 5). After a median follow-up of 4.6 years, no differences in
the frequency of colorectal cancers were observed, nor were there
any differences in the geographical location of second colorectal
primaries. In addition, the addition of supplemental EBRT (i.e.
EBRT–BT) did not increase the risk of colorectal cancer compared
to using BT alone [45].
Of the 8 single institution studies examining SPC following BT
without comparisons to other population groups (Supplemetary
Material Table 5), crude rates range from 0% for any SPC, bladder
and rectal cancer up to 11.1%, 5.5% and 10.4% for any SPC, second
rectal and second bladder cancers respectively [45–52]. It is likely
that some studies have insufﬁcient follow-up to detect all SPCs and
that other single institution studies contain a relatively small num-
ber of patients. The age of the patient population may also have an
impact. For example, Yagi et al. reported no cases of SPC in patients
aged less than 60 but a crude rate of 7.6% in patients aged over 60,
after median follow-up of 4.3 years [50].
Studies examining survival following BT suggest that up to 3%
of patients may die from SPC following BT or EBRT–BT (crude rates,
Supplementary Material Table 2) [51,53,54]. The cumulative haz-
ard of death due to a SPC was found to be 7.2% in one study of
1354 patients treated with either BT or EBRT–BT after 12 years
[53]. In another series, based on competing analysis to take into ac-
count other causes of death, the 10 year risks of death from second
malignancy following BT was 0.8% for out-of-ﬁeld SPC and 0% for
in-ﬁeld SPC in a series of 413 patients [41]. In patients who devel-
oped SPC, the risk of mortality from SPC was no different between
patients treated with BT or EBRT (or surgery) [41].
Overall, evidence from patients treated with BT or EBRT–BT is
encouraging, and is less suggestive of an increased risk of SPCs as
has been observed in studies evaluating patients treated with
EBRT. Three studies have suggested an increase in bladder cancer
beginning in the ﬁrst few years of follow-up, which could be at
least partly attributed to surveillance bias [22,42,43]. Importantly,
there is a suggestion from two of the largest cohorts, that the risk
of a SPC, although low, may increase with time and so it is likely
that follow-up in general has been insufﬁcient to detect all poten-
tial late increases in SPC incidence [10,22].Impact of treatment technique: Proton therapy
Only one study was identiﬁed which reported SPC rates in pa-
tients treated with proton therapy for PCa [16]. Treatment con-
sisted of a photon four ﬁeld box to 50.4 Gy in 28 fractions
followed by a 27 Gy conformal perineal proton boost. After a med-
ian follow-up of 13.1 years, 1 of the 39 patients (2.6%) developed
rectal cancer [16]. Clearly no comparisons to other populations
have been performed and this series is too small to draw any ﬁrm
conclusions. Furthermore, the relative contribution of the EBRT and
proton components cannot be assessed. Larger numbers of patients
treated with proton monotherapy will be required before any con-
clusion can be drawn regarding the impact of proton therapy on
SPC incidence in PCa patients.Post-operative radiotherapy
Five studies using registry data have examined SPC risk in pa-
tients treated with post-operative RT (PORT) following prostatec-
tomy [30,31,33,55,56] (Supplmentary Material Table 6).
Chrouser et al. included a subset of 184 PCa patients managed
with PORT in their registry analysis and compared bladder cancer
incidence to the general population [31]. No increased risk of blad-
der cancer was observed in patients receiving PORT over several
time points.
Compared to patients treated with radical surgery alone, Abdel-
Wahab et al. demonstrated that there was a signiﬁcantly increased
226 Second primary cancer after prostate radiotherapyrisk of a ‘primary pelvic’ SPC (i.e. tumour likely to arise within the
irradiated ﬁeld: includes rectum, bladder, anus, anal canal, anorec-
tum, prostate, other pelvic soft tissue, bone or joint cancers or pel-
vic lymphoma) in patients who received PORT beyond 1 year and
beyond 5 years of follow-up [55]. There was no increase in the risk
of ‘secondary’ pelvic tumours (recto-sigmoid, penis, small intestine
(not duodenum), ureter, other urinary primaries, male genital, tes-
tes and pelvic lymphoma) or non-pelvic tumours beyond 1 and be-
yond 5 years [55].
Ciezki et al. used 20-year competing risk regression to compare
second rectal and bladder cancers between patients treated with
surgery and PORT and those treated with surgery alone [56]. At
20 years, the cumulative incidence of second rectal cancer was
0.74% and 1.06% in patients treated with surgery alone and surgery
followed by PORT respectively. The cumulative incidence of second
bladder cancer at 20 years was 1.7% and 2.7% in patients treated
with surgery alone and surgery plus PORT respectively. Multivari-
ate analysis revealed a signiﬁcantly increased risk of second rectal
and bladder cancers amongst irradiated patients. Older age was
also a signiﬁcant predictor of second bladder cancer (HR: 1.01,
p = 0.003) [56].
Singh et al. observed that patients treated with surgery and
PORT had an increased risk of second bladder cancers overall as
well as beyond 6 months of follow-up (HR: 1.28) compared to pa-
tients treated with neither surgery, nor RT [33]. The risk increased
beyond 5 years and increased further beyond 10 years of follow-up
(HRs: 1.52 and 1.94 respectively). The duration of follow-up in the
PORT group was almost twice that in the comparator group (med-
ian 93.6 and 48.4 months respectively) and so it is possible that the
incidence of bladder cancer was lower in the reference group as a
result of insufﬁcient follow-up [33].
In a small subset of patients, Boorjian et al. did not ﬁnd patients
receiving PORT to be at increased risk of second bladder cancer
over all time periods assessed compared to patients treated with
surgery alone [30].
One series of 214 patients treated with PORT reported death
due to second malignancy in 1.9% of patients after median fol-
low-up of 4.8 years (crude rate) [57] while Ciezki et al. reported
very low age-adjusted mortality rates from second rectal or blad-
der cancers [56] (Supplementary Material Table 2).
Compared to PCa patients who do not receive PORT, there is
therefore a consistent suggestion of an increased risk of second
bladder/rectal cancers following PORT, and this risk appears to in-
crease with time but may also be present early on in the follow-up
period. Compared to the general population the same increase in
risk is not observed, although the number of patients in this partic-
ular analysis was small [31].
Discussion
There is much heterogeneity in the above studies, in terms of
methods, comparisons and results, which makes it difﬁcult to draw
ﬁrm conclusions. Increases in SPC have been observed in irradiated
PCa patients in some studies, more so when compared to non-irra-
diated PCa patients, and less consistently when compared to the
general population. The majority of the evidence suggests that
the risk of SPC increases over time, particularly for SPCs occurring
within the radiation ﬁeld, and if these occur beyond 5 years they
may be considered RISPC.
Solid second primary cancers which occur within 5 years of
irradiation are not generally considered RISPCs. Other explanations
for an excess of early SPCs must therefore be sought. Surveillance
bias is one explanation, as patients presenting with both bladder
and bowel symptoms following RT may be investigated and inci-
dental SPCs may be identiﬁed. Alternatively, there may be genetic
or environmental factors which are common to PCa and other can-cers, and therefore patients with PCa are likely to develop other
cancers, within 5 years of prostate irradiation or beyond. This is
one possible reason for increased cancer rates which have at times
been observed when comparing irradiated PCa patients to the gen-
eral population. If this were the case, then the same increased risk
should be observed when comparing non-irradiated PCa patients
to the general population. In practice, this is not consistently the
case, and non-irradiated PCa patients have been shown to have
similar (or even reduced) rates of secondmalignancy to the general
population in terms of cancer overall, and in terms of rectal and
bladder cancer speciﬁcally [5,6,8,21,24,42]. Surveillance bias is
perhaps therefore a better explanation for increased early SPCs in
irradiated patients. Beyond 5 years, radiation for in-ﬁeld SPCs,
and genetic or environmental factors for either in-ﬁeld or out-of-
ﬁeld SPCs, may potentially contribute.
Differences in comparator group are important to consider
when evaluating relative SPC risks. As well as the general popula-
tion, comparisons have been made with non-irradiated PCa pa-
tients. This patient group might consist of surgically treated
patients, PCa patients treated with neither surgery nor RT, or a
mixture of surgically treated patients and patients treated with
neither surgery, nor RT. Although we did not analyse differences
between these non-irradiated groups in detail, it should not be as-
sumed that any of these PCa patients are pure surrogates for the
general population or that they are equivalent to each other. While
all these non-irradiated patients have PCa, and therefore common
factors contributing to this, there are likely variations in genetic or
environmental factors in each of these patient groups that may
contribute to or reduce the risk of other cancers.
If the non-irradiated comparator group consists of purely surgi-
cally treated patients, selection bias may contribute to differences
in SPC risk between surgically treated and irradiated patients. Pa-
tients who are ﬁt enough to undergo an operation may have funda-
mental differences to patients who are only deemed well enough
to undergo radiotherapy, and as such surgically treated patients
may lack risk factors for certain SPCs.
If the non-irradiated comparator group is patients treated with
neither surgery nor RT, many of these patients may have signiﬁcant
co-morbidities which render them unﬁt for either deﬁnitive treat-
ment. Again, this population of patients will have different risk of
SPC to PCa patients overall. Furthermore, these patients may not
be as thoroughly followed up or investigated for possible second
malignancy compared to ﬁtter healthier patients, thus creating
additional bias in comparisons and under-reporting of SPC rates.
When the non-irradiated comparator group is a mixture of sur-
gically treated patients as well as those who receive no deﬁnitive
therapy, a mixed population is potentially created, consisting of
surgically ﬁt patients and patients unﬁt for any deﬁnitive therapy,
leading to further difﬁculties in making non-biased comparisons.
It has been suggested that comparing irradiated patients to sur-
gically treated patients results in fewer confounding factors than
comparisons to the general population or other non-irradiated
PCa patients [13]. Certainly, in clinical practice, if patients are ﬁt
enough to consider surgery or RT, then it can be argued that this
is the most relevant comparison.
The length of follow-up between comparator groups is also
important, and where this is insufﬁcient in any group and not ade-
quately corrected for, reported outcomes may be inaccurate in that
group.
Smoking is an important potential confounding factor, espe-
cially when considering bladder and lung cancer. As discussed
above, smokers may be refused surgery and therefore cohorts of
patients treated with radiotherapy may contain a higher propor-
tion of smokers, which in turn will increase the risk of SPCs. PCa
patients treated with radiotherapy may also be older than surgi-
cally treated patients and this too may have an impact on risks
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important factor: increasing age has been associated with a re-
duced risk of second cancers within high dose (>5 Gy) regions
[11], while increasing age has been shown to be a signiﬁcant pre-
dictor of bladder SPC [30,33]. Most studies have adjusted for age
when calculating risks [5–8,10–14,21–33,40–42,55,56]. Similarly
most studies have adjusted for race and grade of tumour. It is pos-
sible that other confounding factors exist which are more common
in irradiated than non-irradiated PCa patients, and these may also
contribute to SPC risk within or beyond 5 years.
A recently identiﬁed potential confounding factor is visceral
adiposity [17]. Zilli et al. intended to investigate the impact of total
abdominal adiposity on clinical and pathological PCa features [17].
Incidentally they observed that increased visceral adiposity was an
independent signiﬁcant predictor of SPCs (HR: 1.014; p = 0.0001).
While many of the studies have included patients treated with
now out of date techniques, the registry studies by Neider et al.,
and Boorjian et al. which included patients from 1988 to 2003,
are considered more contemporary EBRT populations, and so the
risks observed in these studies may be considered more relevant
to today’s PCa patients [22,30]. It is worth noting, therefore, that
both of these studies found the risk of bladder cancer to be in-
creased in irradiated patients [22,30], and one demonstrated an in-
creased risk of rectal cancer as well [22]. Insufﬁcient follow-up
(median 3.3 years) may explain the absence of increased rectal
cancer risk from EBRT in the other of these studies [30].
Studies including patients from the 1970s and early 1980s
would have included patients diagnosed before the routine use of
PSA. As such a greater proportion of patients would be diagnosed
with locally advanced disease and as such would have inferior sur-
vival compared to patients in today’s society where many more pa-
tients are diagnosed at an earlier stage. A signiﬁcant proportion of
patients from the past may therefore have died prior to developing
SPC, and so the relative risks of SPC reported from these studies
may actually be lower than what would be expected from modern
day PCa patients [22].
With the advent of more conformal treatments, it was hoped
that SPC risk might reduce, although the clinical evidence to sup-
port this is based on limited evidence from only two relatively
small populations irradiated with IMRT/3D-CRT [13,40,41] and
on extrapolated evidence from two other studies [7,8]. Longer fol-
low-up and larger numbers of patients will be required. Studies
examining the impact of BT or EBRT–BT on SPC risk appear prom-
ising, although, once again, longer follow-up will be required be-
fore deﬁnitive conclusions can be drawn.Conclusions
Given the multiple factors involved, and heterogeneity among
studies, it is very difﬁcult to tease out deﬁnitive answers regarding
irradiation and the risk of SPCs. Putting all the potential confound-
ers and biases aside, however, it must be acknowledged that a
small increased risk of SPC and RISPC in irradiated PCa patients
has been observed in several studies. The risk of RISPC appears
small, in the range of 1 in 220 to 1 in 290 over all durations of fol-
low-up, based on older radiation techniques. Importantly, the risk
appears to increase with time, and beyond 5 years, SPCs in the re-
gion of the original ﬁeld may be considered RISPCs. To date there
are insufﬁcient clinical data to draw ﬁrm conclusions about the im-
pact of more modern RT techniques, although limited evidence is
encouraging. As PCa survival improves, the risk of second
malignancy becomes more relevant, especially when treating
younger patients. Second primary cancer risks must therefore be
borne in mind when considering which patients to irradiate and
which techniques to employ.Acknowledgment
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